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Lower urinary tract infections are very common diseases. Recurrent urinary tract infections remain challenging to
treat because the main treatment option is long-term antibiotic prophylaxis; however, this poses a risk for the
emergence of bacterial resistance. Some options to avoid this risk are available, including the use of cranberry
products. This article reviews the key methods in using cranberries as a preventive measure for lower urinary tract
infections, including in vitro studies and clinical trials.
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INTRODUCTION
Lower urinary tract infections (UTIs) are very common and
have been estimated to occur in at least 60% of women at some
stage during their lives (1-3). Because of their high prevalence,
UTIs are a public health concern, having an estimated cost of
diagnosis and treatment exceeding US $25 billion over a 20-
year period (approximately US $2.47 billion in the year 2000)
(1,4). UTIs are approximately 50-fold more common in adult
females than males because women have shorter urethras that
allow bacteria to ascend into the bladder. The first step in an
infection is the colonization of the periurethral tissues,
followed by the passage of bacteria through the urethra. The
second step is the adherence of bacteria to the urethra and
bladder walls and proliferation (5,6).
UTIs are caused by microorganisms, mainly Gram-
negative bacteria. Indeed, Escherichia coli (E. coli) account
for most cases (2,3,5). Treatment usually involves antibio-
tics, and recurrence is a major concern (7). The risk factors
that predispose women to recurrent UTIs include sexual
intercourse, the use of contraception, antimicrobial resis-
tance, menopause, genetics and bacterial virulence (2).
Focusing on UTI prevention became a major goal because
of their recurrent nature, increasing antimicrobial resistance
and medical costs (8). The current management of recurrent
UTIs involves either repeated courses of antibiotics or low-
dose, long-term antibiotic prophylaxis (2). Although effec-
tive, these treatments have side effects, such as fungal
super-infection (oral or vaginal thrush) and gastrointestinal
infections, notably Clostridium difficile (9).
CRANBERRIES
Cranberry is a term derived from the contraction of
‘‘crane berry.’’ This name is derived from the nickname of
the bilberry flower, which, when it withers, is similar in
appearance to the head and neck of the sand crane, a bird
that often feeds on the berries of this plant (10). The
cranberry is part of the Ericaceae family and naturally
grows in acidic swamps full of peat moss in humid forests
(11).
The American cranberry (Vaccinium macrocarpon) was
historically used by North American Indians to treat UTIs
(10). There are other relatives of the cranberry family
(European cranberry – V. oxycoccus; lingonberry – V. vitis-
idaea; blueberry – V. myrtillus) that share some of the
cranberry’s basic components, but research evidence for a
role in prevention is limited (12,13).
Cranberries are composed of water (88%), organic acids
(including salicylate), fructose, vitamin C (high levels, i.e.,
200 mg/kg of fresh berries), flavonoids, anthocyanidins,
catechins, and triterpinoids (10). The chemical constituents
responsible for their taste are the iridoid glycosides. The
anthocyanidins and proanthocyanidins (PAC) are tannins
(stable polyphenols) found only in vaccinium berries and
function as a natural plant defense system against microbes
(10,14).
Common preparations with cranberries include fresh,
whole berries, gelatinized products, juices (usually 10-25%
pure juice) and capsules (10-16). Pure juice is too acidic
(pH,2.5) and unpalatable, even with sweeteners (10).
Despite cranberry presentation, it is generally recom-
mended to consume cranberries just prior or two hours
after meals; it is also important to drink lots of water, mainly
after preparations from dehydrated juices (11). Cranberry
juice, predominantly in the form of a juice cocktail drink
with approximately 25% cranberry juice, has been the
traditional choice of most women seeking to prevent UTIs.
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MECHANISM OF ACTION
One important property of E. coli is its adherence to the
host tissue. The main protein structure related to this
phenomenon is the adhesin protein, and its name is based
on its shape: pili or fimbriae (2). Bacterial adhesion is
accomplished by the binding of lectins exposed on the cell
surfaces of these fimbriae to complementary carbohydrates
on the host tissues. Pili are small filaments that enable
bacteria to adhere to the host tissue; these proteins can be
either mannose-resistant or mannose-sensitive. The man-
nose-sensitive pili, called type 1 pili, permit bacterial
adhesion to the urothelium; the fimbriae are inhibited by
fructose (present in grapes, oranges, and cranberries). The
more virulent strains of E. coli, isolated from patients with
pyelonephritis and recurrent UTIs, have other types of
fimbriae, notably p-fimbriae (pyelonephritis fimbriae).
These fimbriae bind to glycosphingolipids of the lipid
double membrane of renal cells, which precedes renal
parenchymal invasion (6).
The current hypothesis is that cranberries work princi-
pally by preventing the adhesion of type 1 and p-fimbriae
strains (particularly from E. coli) to the urothelium (17-20).
Without adhesion, the bacteria cannot infect the mucosal
surface. In vitro, this adhesion is mediated by two
components of cranberries: fructose, which inhibits the
adherence of type 1 fimbriae (18,21), and PAC, which
inhibits the adherence of p-fimbriae (22,23). The binding of
the proteinaceous bacterial fimbrial tips to mucosal surfaces
on the uroepithelium occurs as a specific receptor–ligand
association favored by hydrophobic interactions. One
possible mechanism is that the cranberry compounds, acting
as receptor analogs, competitively inhibit the adhesion of
E. coli to host cells by binding to the fimbrial tips. The in
vitro anti-adherence effect of cranberries is dose-dependent
(15,19,24,25).
Another mechanism of cranberry activity is the in vitro
reduction in the expression of p-fimbriae in E. coli by
changing the conformation of surface molecules (19,26).
Lavigne et al. (24) demonstrated that cranberries can
decrease the virulence of E. coli strains. Furthermore, they
described a reduction in adherence activity even in strains
with no expression of type 1 fimbriae or p-fimbriae, which
adhere via an adhesin, suggesting that cranberry extracts
affect a variety of fimbriae. In a recent study, pH-
neutralized cranberry juice induced conformational changes
in the surface macromolecules of p-fimbriated E. coli by
specifically reducing fimbrial length and density (26).
Despite data suggesting that PACs are the active moieties
in cranberries, there is doubt regarding the route from
ingestion through urinary excretion. Some authors believe
that intact PACsmay not be active in vivo because they are too
large to be absorbed as intactmolecules in the gastrointestinal
tract (27,28). However, PAC dimers and trimers are perme-
able in the Caco-2 human intestinal cell line, suggesting that
they could be absorbed intact (29). There are few studies
assessing PAC excretion in humans (30,31). Valentova et al.
(32) measured low levels of anthocyanins and PAC oligomers
in urine after the consumption of 1200 mg of dried cranberry
juice. Experimental studies concerning human anthocyanins
absorption after cranberry juice consumption demonstrated
that only 0.078 to 5% of the anthocyanins are excreted in the
urine (31,33). Peak urinary anthocyanidin concentration is
observed 3-6 hours after intake, and urinary excretion is
nearly complete within the first 12 hours (31). Another
possibility is that PAC (or its metabolites) could be active in
the colon and the urinary tract (18). They could bind to
uropathogenic rectal E. coli isolates, thereby rendering them
anti-adherent prior to their possible introduction into the
urinary tract. Indeed, they could alter the bacterial selection
pressure in the colon to favor nonadherent strains (30).
Most studies have focused on uropathogenic E. coli type 1
and p-fimbriated E. coli, but there are many in vitro studies
showing an inhibition of adherence for Proteus spp., P.
aeruginosa, E. faecalis, S. aureus, S. typhimurium and K.
pneumoniae (10,34,35). Even multi-drug resistant strains of
E.coli exhibited inhibition of adherence to uroepithelial cells
in the presence of proanthocyanidin (36).
There are many in vitro studies (15,16,19,24,25,32,35)
confirming the anti-adherence activity of cranberries
(Table 1). The biosafety of cranberries has been tested, and
no biochemical or hematological alterations were identified.
Tao et al. (37) demonstrated that cranberry juice could
decrease E. coli adhesion up to 8 hours after consumption.
Concomitant use of cranberries with antibiotics has been
tested. Li et al. (38) performed a study on b-lactam antibiotic
(i.e., amoxicillin and cefaclor) absorption when adminis-
tered with cranberry juice and reported a modest delay in
absorption; however, total absorption was not affected; this
delay was deemed not clinically significant. It is also
important to know that the anti-adherence activity asso-
ciated with cranberry consumption is not related to
antibiotic sensitivity or resistance (16).
Despite all of these data, there is still no clear under-
standing of how cranberry PAC is absorbed, metabolized
and excreted in urine to result in the protective action
against bacterial adherence.
CLINICAL TRIALS
Cranberries have been tested for their clinical relevance in
many different conditions. They have been evaluated in the
treatment of UTIs but were deemed ineffective (2,7,14,24).
Cranberries were also studied for UTI prophylaxis chiefly in
women, but also in children and men; additionally, they
have been studied in conditions such as neurogenic bladder
and pregnancy, as summarized in Table 2 (12,39-52). Most
clinical interest in the use of cranberries is for cystitis
prevention. In the 2008 Cochrane Database of Systematic
Reviews, there were ten randomized trials regarding UTI
prevention on a total of 1,049 patients. They concluded that
there is some evidence that cranberry juice may decrease the
number of symptomatic UTIs over a 12 month period,
particularly, and only, for women with recurrent UTIs (53).
Limitations included the dose, type of drug administration
(juice or capsules), treatment duration, and type of subjects.
For UTI prevention in young women, there are three
randomized studies (cranberry versus placebo) in women
with recurrent UTIs. Walker et al. (39) determined inci-
dences of UTIs of 2.4 subjects/year in the cranberry arm and
6.0 subjects/year in the placebo arm (p,0.0005). Stothers
et al. (40) tested both cranberry juice and tablets versus
placebo in women aged 21 to 72 years old and found that
32% of the placebo group contracted a UTI, whereas 20% of
the cranberry juice group (p,0.05) and 18% of the tablets
group (p,0.05) contracted UTIs. He also estimated the
annual cost of juice and tablets to be US $1,400 and US $624,
respectively; the average cost-effectiveness ratios for tablets
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and juice were US $1,890 and US $3,333, respectively, per
UTI prevented.
However, Barbosa-Cesnik et al. (41), using a double-blind,
placebo-controlled trial, reported a UTI recurrence of 19.3%
in individuals consuming 8 oz. of 27% cranberry juice daily
versus 14.6% for placebo, with no significant difference
between the groups (p = 0.21). Kontiokari et al. (12) used a
cranberry-lingonberry (CB) juice versus Lactobacillus GG
versus control (no treatment) and measured a risk reduction
of 20% when the CB group was compared to the control
group. After 12 months, 24%, 43% and 38%, of the CB,
Lactobacillus GG and control groups, respectively, had
experienced at least 1 UTI.
Elderly men and women have been evaluated for UTI
prevention using cranberries in several trials. McMurdo et
al. (42) studied 376 hospitalized patients over 60 years old in
two groups: cranberry juice versus placebo in a 24-day trial.
Of the patients in the placebo group, 7.4% developed
symptomatic UTIs, and 3.7% in the cranberry group
developed a UTI (p =not significant). In a six month trial,
Avorn et al. (43) compared cranberry juice versus placebo
and found that there was a 4% bacteriuria and pyuria
presence concurrent with UTI symptoms in the cranberry
group (n = 473) versus 7% in the placebo group (n = 498)
(p=not significant). Therefore, the evidence to recommend
cranberries for UTI prevention in the elderly is inconclusive.
To evaluate UTIs and lower urinary tract symptoms in
male and female patients undergoing radiotherapy treat-
ment for bladder or cervical cancer, cranberry juice was
administered twice daily for six weeks in a randomized,
double-blind, placebo-controlled trial. There was no statis-
tical difference between the groups for the incidence of UTIs
(44.1% for cranberry and 38.3% for placebo, p= 0.267);
however, possible explanations for this result could be the
small number of patients and poor compliance (54).
Cranberries have been compared with trimethoprim for
UTI prevention in a randomized, controlled study in
women older than 45 (44). The six-month risk of developing
a UTI while consuming cranberries was 60% greater than in
women on low-dose trimethoprim; however, this result did
not reach statistical significance.
One study evaluated the use of cranberry juice to prevent
UTIs during pregnancy (45). Women less than 16 weeks
pregnant were randomized into three groups: one con-
sumed cranberries three times daily (n = 58), another
consumed cranberries only in the morning and then a
placebo (n = 67) and the third group consumed the placebo
three times daily (n = 63). There were four UTIs and 23 cases
Table 1 - In vitro activity of cranberries against bacteria.
Study N Study design Cranberry preparation Micro-organism Results
Pinzon-Arango
et al., 2009
- In vitro bacteria cultured
in medium and human
uroepithelial cell culture
PAC of 0, 64, 128 and
345.8 mg/ml
E.coli E. coli cultured in the presence
of PAC inhibited adhesion from
50.2 to 7.9 bacteria/cell
(p,0.01); dose-dependent
effect.
Lee et al.,
2010
Phase 1, N = 20
(16 women,
4 men); phase 2
(7 women, 2 men)
N = 9.
In vitro urine activity
after cranberry consumption
in volunteers
275 mg of whole, dry
cranberries and 25 mg of
concentrated, dry
cranberries
E. coli,
K. pneumonia and
C. albicans
Phase 1: anti-adhesion activity
in 35% (E. coli), 65% (K.
pneumoniae) and 45% (C.
albicans). Phase 2: anti-
adhesion activity in 23% (E.
coli), 33% (c. albicans) and 67%
(K. pneumoniae).
Lavigne et al.,
2007
N = 8 females In vitro urine activity after
cranberry consumption in
volunteers with crossover
36 mg cranberry capsules
of; daily dosage was 36 or
108 mg or placebo
E. coli Dose-dependent effect on anti-
adhesion activity (p,0.001).
Virulence reduction when E. coli
tested against worms
(p,0.00001).
Gupta et al.,
2007
In vitro anti-adhesion activity
against bladder and vaginal
epithelial cells
Cranberry capsule with
2.7 mg of PAC diluted
from 0 to 75 mg/ml
E. coli Dose-dependent effect on anti-
adhesion activity of PAC against
E. coli from 6.9 to 2.2 and 1.6
bacteria/cell following PAC at 0,
25 and 50 mg/ml, respectively
(p,0.001).
Howell et al.,
2010
N = 32 females Multicentric, randomized,
double-blind in vitro urine
activity after cranberry
consumption in volunteers
Cranberry capsule of 0,
18, 36 or 72 mg of PAC
E. coli Dose-dependent effect of anti-
adhesion activity increasing
with the amount of PAC.
Virulence was also reduced with
PAC in a dose-dependent
fashion.
Valentova
et al., 2007
N = 65 females Double-blind, placebo-
controlled in vitro urine. Group
I (n = 23) placebo; group II
(n = 20) 400 mg; group III
(n = 22) 1200 mg
400 mg or 1200 mg per
day of dried cranberry
juice
S. aureus, E. faecalis,
E. coli, P. aeruginosa,
E. faecium and
K. pneumoniae
Anti-adhesion activity in a dose-
dependent fashion (p,0.05);
highest activity observed
against P. aeruginosa.
Di Martino
et al., 2006
N = 20 (10 males, 10
females)
Double-blind, randomized,
placebo-controlled in vitro
urine activity after cranberry
consumption in volunteers
250 or 750 ml of 27%
cranberry juice
E. coli Dose-dependent decreases in
bacterial adhesion to human
epithelial cell line of 45% and
62% for 250 and 750 ml of
cranberry juice, respectively
(p,0.05), independent of
antibiotic resistance.
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of asymptomatic bacteriuria, but there was no significant
difference with regard to the numbers of UTIs between the
groups. Compliance and tolerability were considerable
obstacles in this study. Of the 188 subjects, 38.8% did not
complete the study and withdrew, most because of
gastrointestinal upset, including nausea, vomiting, diarrhea,
and bad taste.
There are several trials for patients with neurogenic
bladder and under intermittent catheterization (IC). The
study with the largest number of participants (n = 305) is
made up of four different treatment groups (1- methena-
mine hippurate (MH); 2-cranberries 800 mg; 3-MH +
cranberries; and 4-placebo). The follow-up at six months
did not determine a significantly longer UTI-free period in
any of the regimens (46). McGuiness et al. (47) studied 135
patients with multiple sclerosis and found that 34.6% of the
patients receiving less than 8000 mg of cranberries and
32.4% of the patients receiving placebo developed a UTI
(p=not significant). One study by Hess et al. (55) reported a
preventative effect for cranberries in UTIs. They rando-
mized patients with spinal cord injuries into two groups
(i.e., 500 mg of cranberries or placebo). After six months, the
patients alternated groups for six more months. They
observed a reduction in the likelihood of UTIs for all
patients receiving cranberries (p,0.05) and determined that
fewer subjects developed UTIs during the cranberry phase
(13%) compared with the placebo phase (34%, p = 0.03).
For patients with IC, two randomized trials have been
published, both in adults with spinal cord injuries. One
study had 74 participants divided in two groups receiving
Table 2 - Clinical trials of cranberry products for UTI prevention in different populations.
Study N Study design Treatment Results
Walker et al.,
1997
19 young women with
recurrent UTIs
Double-blind, randomized,
placebo-controlled,
crossover trial
400 mg of
cranberry capsules
Withdrawal rate of 47.4%. UTI
incidences were 2.4/subject-year-
cranberry and 6.0/subject-
year-placebo (p,0.005).
Stothers,
2002
150 women with
recurrent UTIs
Double-blind, randomized,
placebo-controlled
250 ml pure cranberry juice or
concentrated cranberry tablets
UTIs were 72% (placebo), 30% (juice;
p,0.05) and 39% (tablets; p,0.05).
Barbosa-
Cesnik,
2010
319 young women with
previous UTIs
Double-blind, randomized,
placebo-controlled
8 oz. of 27% cranberry juice Recurrence rates of UTIs were 19.3%
for cranberry treatment and 14.6%
for placebo (p=0.21).
Kontiokari
et al., 2001
150 young women with
previous UTIs
Double-blind, randomized,
placebo-controlled
50 ml of cranberry-lingonberry
juice (7.5 g of cranberries);
Lactobacillus GG 100 ml/day;
or controls,
20% reduction in UTIs in cranberry
group. Recurrence rate of UTIs lower
in cranberry group (at six months,
p=0.014 and at 12 months, p=0.052).
McMurdo
et al., 2005
376 hospitalized patients
older than 60 years
Double-blind, randomized,
placebo-controlled
150 ml of cranberry juice
(25%) and placebo
Withdrawal rate of 31%. Symptomatic
UTI incidences of 7.4% with placebo
and 3.7% with cranberry
(p=no significance).
Avorn et al.,
1994
153 elderly women Double-blind, randomized,
placebo-controlled
300 ml/day of cranberry
juice and placebo
Bacteriuria in 28.1% in placebo
group and 15% in cranberry group
(no significance). OR of 0.42 for
bacteriuria in cranberry.
McMurdo
et al., 2009
137 women aged .45 years
with recurrent UTIs
Double-blind, randomized
controlled trial
500 mg of cranberry extract
or 100 mg of trimethoprim
25 UTIs in the cranberry group and
14 in the trimethoprim group;
relative risk 1.616, p=0.084.
Wing et al.,
2008
188 pregnant women;
gestation of ,16 weeks
Double-blind, randomized,
placebo-controlled
240 mg of cranberry juice
(27%) 3 times/day (group A)
or 240 mg once daily (group B)
or placebo (group C)
Withdrawal rate of 38.8% (A 50.7%;
B 39.7%; C 55.5%). No significant
differences between the groups
(p=0.71)
Lee et al.,
2007
305 patients with
neurogenic bladder
due to spinal cord injury
Double-blind, randomized,
placebo-controlled
Group 1- methenamine hippurate
(MH); 2- cranberry 800 mg; 3- MH +
cranberry; and 4- placebo
No differences for symptomatic
UTIs comparing groups of
intervention to placebo.
Mc Guinness
et al., 2002
135 patients with
neurogenic bladder
due to multiple sclerosis
Double-blind, randomized,
placebo-controlled
8000 mg of cranberry
capsules or placebo
34.6% contracted a UTI on cranberries
and 32.4% on placebo (p=no
significance). Similar results under
intermittent catheterization.
Waites et al.,
2004
74 patients with
neurogenic bladder
due to spinal cord injury
Double-blind, randomized,
placebo-controlled
1 g of cranberry capsules
or placebo
26 patients withdrew. No differences in
bacteriuria, pyuria or symptomatic UTIs.
Linsenmeyer
et al., 2004
37 patients with
neurogenic bladder
due to spinal cord injury
Double-blind, placebo-
controlled with crossover
400 mg of cranberry tablets
for 4 weeks or placebo
16 patients withdrew. No reductions in
bacteriuria or pyuria with cranberry.
Foda et al.,
1995
40 neurogenic bladder
children under intermittent
catheterization
Single-blind, randomized
with crossover
Cranberry juice 15 mg/kg/day
or water
19 children withdrew. No differences
between groups for asymptomatic
bacteriuria or UTIs.
Schlager et
al., 1999
15 children with
myelomeningocele under
intermittent catheterization
Double-blind placebo-
controlled with crossover
Cranberry juice 60 ml/day
or placebo
No significant differences between
groups regarding bacteriuria or
symptomatic UTI.
Ferrara et al.,
2009
84 girls with recurrent UTIs Randomized controlled Cranberry-lingonberry juice
50 ml/day (n = 27); Lactobacillus
GG 100 ml 5 days/month (n = 26);
control (n = 27)
UTIs in 18.5% (5/27) of patients in the
first group versus 42.3% in the second
and 48.1% in the control group
(p,0.05)
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either 2 g of cranberries or placebo. No differences were
observed in pyuria, bacteriuria, or episodes of symptomatic
UTIs (48). The other study had 21 patients randomly
assigned to 1,200 mg/day of cranberry tablets or placebo
for four weeks and then patients crossed over to the other
group after a washout period. No statistically significant
protective effect was observed for cranberry consumption in
this population (49).
In pediatric populations, there are two studies concerning
children with neurogenic bladder under IC. Foda et al. (50)
studied 40 children; however, only 21 completed the study.
They randomized two groups receiving 15 ml/kg/day of
cranberry juice and water for six months and then crossed
over to placebo with no washout period. No statistical
difference was observed. In another study, 15 children were
randomized into two groups that received either cranberries
or placebo for three months and then crossed over. No
statistical differences were observed for bacteriuria or UTIs
(51). Ferrara et al. (52) performed a study involving young
girls ranging from 3 to 14 years old with recurrent UTIs.
They conducted a six-month, randomized trial comparing a
50 ml daily cranberry-lingonberry juice to 100 ml, five days
per month of Lactobacillus GG drink containing 46107
colony-forming units or placebo. Over this time period,
they observed UTIs in 18.5%, 42.3%, and 48.1% of the
children in each group, respectively (p,0.05).
The recommended doses of cranberry products for the
prevention of UTIs have been poorly defined, and beverage
formulations vary widely. The most highly studied for-
mulation has 25% pure juice (13). Clinical research suggests
that daily dosages of 240–300 ml of cranberry juice cocktail
can prevent 50% of the recurrences of UTIs and can reduce
bacteriuria (11,15,16,30). An ex vivo study examining human
urine following cranberry juice cocktail consumption
suggests that twice-daily dosages of cranberries (36 mg of
PAC) might offer additional protection during a 24 h period
(25,28). Recommended doses of dried, concentrated juice
extract range from 600 to .1,200 mg/day (56) divided into
two or three daily doses. It is important to consider that
dried cranberry extract can be broken down by exposure to
light, heat or cold. However, the addition of vitamins C and
E exert a stabilizing influence (57).
ADHERENCE TO TREATMENT
The number of patient withdrawals in most studies
varied considerably, ranging from 0 to 55%. Additionally,
adherence to treatment was not high; some trials observed
less than 80% adherence (13,53). Reasons for dropout
included: pregnancy, unrelated infections requiring anti-
biotic therapy, moving from the area, and gastrointestinal
symptoms. In children in particular, taste was the main
reason for stopping therapy (50).
Other important issues are the cost and the necessity to
carry large amounts of cranberry juice that may limit
acceptance in general population. Cranberry products at
high doses can be expensive (over US $1,000 annually) (10).
In Brazil, the usual dose intake would cost between US
$1,000 to $1,200 annually. Caloric load in some formulations
was also the cause of some withdrawals. This could indicate
that cranberry juice is not an acceptable therapy over a long
time period.
Side effects commonly reported include the following:
reflux, mild nausea, frequent bowel movements, headaches,
elevation in blood glucose levels, and a cutaneous reaction.
There are some concerns about the potential for cranberries
to cause thrombocytopenia and nephrolithiasis (58,59).
There is one report of immune-mediated thrombocytopenia
after the ingestion of an unknown amount of cranberry
juice. Four studies evaluated the potential risk for lithiasis
(60-63); however, none have shown an increased risk,
though some reported elevated oxalate in the urine that
could potentially enhance the risk for oxalate stones.
Nonetheless, another study described a protective effect
after cranberry usage, an increase in citrate excretion and a
reduction in oxalate excretion.
DRUG INTERACTIONS
Flavonoids, the major constituent of cranberries, have an
established effect on the cytochrome P450 (CYP) drug-
metabolizing enzyme. Flavonoids are also aromatase inhi-
bitors, which are crucial enzymes in estrogen biosynthesis.
Cranberry juice also confers a significant reduction in the
activity of nifedipine oxidase (CYP3A4), thus reducing oral
clearance by 39% and increasing the serum concentration/
time curve (64).
There are some reports of interactions between cranberry
juice and warfarin (65,66). Increases in the international
normalized ratio (INR) of prothrombin time values were
reported in these patients; one patient died as a result of
gastrointestinal and pericardial hemorrhage (67). Potential
mechanisms of this interaction have included the salicylate
content of the juice (68) and the presence of CYP enzyme-
inhibiting flavonoids. There are other studies suggesting
that the potential interaction is low; however, the dosage
was low (250 ml of juice daily). The effect of more than
1,000 ml/day has not been evaluated. A placebo-controlled
study using volunteers found that cranberries increased
sensitivity to the dynamic effects of warfarin. However, a
systematic evaluation of in vitro and in vivo interactions
determined that cranberries could inhibit warfarin hydro-
xylation in vitro, but cranberry juice had no effect on
warfarin clearance in vivo. This lack of concordance reflects
the fact that the site of warfarin metabolism (liver) is
different from the site of exposure to the inhibitory
components in the cranberry juice (intestine) (69). Aside
from these data, the effect of purified PAC on drug
metabolism is unknown. There are many discrepancies in
the published data that make comparisons difficult, includ-
ing the type of cranberry product used, the amount of
cranberry ingested, the type of subjects and comorbidities.
In vitro studies suggest a possible effect of PAC, the active
compound in cranberries that inhibits the adhesion of p-
fimbriated bacteria, mainly E. coli, to the urothelium. Similar
effects on activity in vivo are not found in the literature.
In 2008, the Cochrane review supported cranberry
potential use only in recurrent UTI prophylaxis for young
women. Even for this indication, further clinical trials
(double-blinded, randomized, placebo-controlled) dis-
played no differences between cranberry consumption and
controls. The efficacies in other groups of subjects, such as
the elderly or pediatric populations with neurogenic
bladder, are even more questionable.
Patient withdrawal rates in studies are high due to cost,
taste and gastrointestinal intolerance. However, patients
should be aware of drug interactions (mainly warfarin) that
may even have potentially fatal consequences. Using the
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current available data, the use of cranberries cannot be
scientifically promoted for UTI prevention. Future studies
should focus on PAC, the active compound in cranberries,
instead of the whole fruit.
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